Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEARNER: Low Dose Aspirin in Pregnant Women With Sickle Cell Disease
NCT06417411Phase 2Active, not recruiting
- Sponsor
- Instituto Nacional de Investigação em Saúde
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aspirin in sickle cell disease (SCD), pregnancy complications and preeclampsia (2 arms), sponsored by Instituto Nacional de Investigação em Saúde. Primary endpoints: Maternal Mortality at 2 years, Life Birth Related Events at 2 years and 1 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
sickle cell disease (SCD)pregnancy complicationspreeclampsia
Beyond the preview
Go deeper on NCT06417411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417411.